Gene alterations and apoptosis in rhabdomyosarcoma

Fetal and Pediatric Pathology

Volumn 17, Issue 2, 1997, Pages 233-247

  Boman, Françoise ^a   Brel, Didier ^a   Antunes, Laurent ^a   Alhamany, Zaïtouna ^b   Floquet, Jean ^a   Boccon Gibod, Liliane ^c  

^a CHU NANCY BRABOIS   (France)

^b Rabat Institut   (Morocco)

^c ARMAND TROUSSEAU HOSPITAL   (France)

Author keywords

apoptosis; childhood; oncogene; rhabdomyosarcoma; tumor suppressor gene

Indexed keywords

ADOLESCENT; APOPTOSIS; ARTICLE; CHILD; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; INFANT; MALE; PATHOLOGY; PRESCHOOL CHILD; RETROSPECTIVE STUDY; RHABDOMYOSARCOMA; SOFT TISSUE TUMOR; CHILDHOOD CANCER; CLINICAL ARTICLE; GENE EXPRESSION; HUMAN TISSUE; IN SITU HYBRIDIZATION; ONCOGENE C MYB; PRIORITY JOURNAL; SOFT TISSUE CANCER; TUMOR SUPPRESSOR GENE;

ADOLESCENT; APOPTOSIS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; MALE; RETROSPECTIVE STUDIES; RHABDOMYOSARCOMA; SOFT TISSUE NEOPLASMS;

PROTEIN P53;

EID: 0031089751     PISSN: 15513815     EISSN: 15513823     Source Type: Journal    
DOI: 10.1080/15513819709168568     Document Type: Article

References (47)

1. Enzinger FM, Weiss SW. Soft Tissue Tumors. 3rd ed. St. Louis: Mosby, 1995.
2. Weiss SW. Histological Typing of Soft Tissue Tumors. International Histological Classification of Tumours. World Health Organization. 2nd ed. Berlin: Springer-Verlag, 1994.
3. Tsokos M. The diagnosis and classification of childhood rhabdomyosarcoma. Semin Diagn Pathol 1994;11:26-38. (Pubitemid 24092133)
4. Asmar L, Gehan EA, Newton WA, et al. Agreement among and within groups of pathologists in the classification of rhabdomyosarcoma and related childhood sarcomas: Report of an international study of four pathology classifications. Cancer 1994;74:2579-88. (Pubitemid 24320865)
5. Cavazzana AO, Schmidt D, Ninfo V, et al. Spindle cell rhabdomyosarcoma: A prognostically favorable variant of rhabdomyosarcoma. AmJ Surg Pathol 1992;16:229-35.
6. Leuschner I, Newton WA, Schmidt D, et al. Spindle cell variants of embryonal rhabdomyosarcoma in the paratesticular region: A report of the Intergroup Rhabdomyosarcoma Study. Am J Surg Pathol 1993;17:221-30. (Pubitemid 23085916)
7. Tsokos M, Webber BL, Parham DM, et al. Rhabdomyosarcoma: A new classification scheme related to prognosis. Arch Pathol Lab Med 1992;116:847-55.
8. Scrable HJ, Witte DP, Lampkin BC, Cavenee WK. Chromosomal localization of the human rhabdomyosarcoma locus by mitotic recombination mapping. Nature 1987;329:645-7. (Pubitemid 17140118)
9. Parham DM, Shapiro DN, Downing JR, Webber BL, Douglass EC. Solid alveolar rhabdomyosarcomas with the t(2;13): Report of two cases with diagnostic implications. AmJ Surg Pathol 1994;18:474-8. (Pubitemid 24134088)
10. Sawyerj R, Crussi FG, Kletzel M. Pericentric inversion (2) (pl5q35) in an alveolar rhabdomyosarcoma. Cancer Genet Cytogenet 1994;78:214-8.
11. Davis RJ, D'Cruz CM, Lovell MA, Biegel JA, Barr FG. Fusion of PAX7 to FKHR by the variant t(l;13)(p36;ql4) translocation in alveolar rhabdomyosarcoma. Cancer Res 1994;54:2869-72. (Pubitemid 24187765)
12. Cordon-Cardo C, Latres E, Drobnjak M, et al. Molecular abnormalities of mdm2a.nd p53genes in adult soft tissue sarcomas. Cancer Res 1994;54:794-9. (Pubitemid 24068339)
13. Drobnjak M, Latres E, Pollack D, et al. Prognostic implications of p53 nuclear overexpression and high proliferation index of Ki-67 in adult soft-tissue sarcomas. J Natl Cancer Inst 1994;86:549-54. (Pubitemid 24111011)
14. Latres E, Drobnjak M, Pollack D, et al. Chromosome 17 abnormalities and TP5B mutations in adult soft tissue sarcomas. AmJ Pathol 1994;145:345-55. (Pubitemid 24245835)
15. Forus A, Florenes VA, Maelandsmo GM, Meltzer PS, Fodstad O, Myklebost O. Mapping of amplification units in the ql3-14 region of chromosome 12 in human sarcomas: Some amplica do not include MDM2. Cell Growth Differ 1993;4:1065-70. (Pubitemid 2020828)
16. Florenes VA, Maelandsmo GM, Forus A, Andreassen A, Myklebost O, Fodstad O. MDM2 gene amplification and transcript levels in human sarcomas: Relationship to TP53gene status. J Nad Cancer Inst 1994;86:1297-302. (Pubitemid 24276791)
17. Dias P, Kumar P, Marsden HB, Gattamaneni HR, HeighwayJ, Kumar S. N-mjcgene is amplified in alveolar rhabdomyosarcomas (RMS) but not in embryonal RMS. IntJ Cancer 1990;45:593-6. (Pubitemid 20146113)
18. Driman D, Thorner PS, Greenberg ML, Chilton-MacNeill S, Squire J. MYCN gene amplification in rhabdomyosarcoma. Cancer 1994;73:2231-7. (Pubitemid 24107982)
19. Castle VP, Heidelberger KP, BrombergJ, Ou X, Dole M, Nunez G. Expression of the apoptosis-sup-pressing protein bcl-2 in neuroblastoma is associated with unfavorable histology and N-myc amplification. AmJ Pathol 1993;143:1543-50. (Pubitemid 24058257)
20. Hockenbery D. Defining apoptosis. AmJ Pathol 1995;146:16-9.
21. Trojani M, Contesso G, Coindre JM, et al. Soft-tissue sarcomas of adults: Study of pathological prognostic variables and definition of a histopathological grading system. IntJ Cancer 1984;33:37-42. (Pubitemid 14223231)
22. Costa J, Wesley RA, Glatstein E, Rosenberg SA. The grading of soft tissue sarcomas: Results of a clinicohistopathologic correlation in a series of 163 cases. Cancer 1984;53:530-41. (Pubitemid 14182732)
23. Staunton MJ, Gaffney EF. Tumor type is a determinant of susceptibility to apoptosis. AmJ Clin Pathol 1995;103:300-7.
24. Wyllie AH. Apoptosis (the 1992 Frank Rose Memorial Lecture). BrJ Cancer 1993;67:205-8. (Pubitemid 23049537)
25. Mulligan LM, Matlashewski GJ, Scrable HJ, Cavenee WK. Mechanisms of p53 loss in human sarcomas. Proc Nad Acad Sci USA 1990;87:5863-7.
26. Stratton MR, Moss S, Warren W, et al. Mutation of the p53 gene in human soft tissue sarcomas: Association with abnormalities of the RBI gene. Oncogene 1990;5:1297-301.
27. Toguchida J, Yamaguchi T, Ritchie B, et al. Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res 1992;52:6194-9.
28. Felix CA, Chavez Kappel C, Mitsudomi T, etal. Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res 1992;52:2243-7.
29. Soini Y, Vahakangas K, Nuorva K, Kamel D, Lane DP, Paakko P. p53 immunohistochemistry in malignant fibrous histiocytomas and other mesenchymal tumours. J Pathol 1992;168:29-33.
30. Dei Tos AP, Doglioni C, Laurino L, Barbareschi M, Fletcher CDM. p53 protein expression in non-neoplastic lesions and benign and malignant neoplasms of soft tissue. Histopadiology 1993; 22:45-50. (Pubitemid 23043994)
31. Kawai A, Noguchi M, Beppu Y, et al. Nuclear immunoreaction of p53 protein in soft tissue sarcomas: A possible prognostic factor. Cancer 1994;73:2499-505. (Pubitemid 24155524)
32. Oliner JD, Pietenpol JA, Thiagalingam S, GyurisJ, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals die activation domain of tumour suppressor p53. Nature 1993;362:857-60. (Pubitemid 23132165)
33. Barak Y, Juven T, Haffner R, Oren M. mdw.2 expression is induced by wild type p53 activity. EMBO J 1993;12:461-8. (Pubitemid 23073692)
34. Juven T, Barak Y, Zauberman A, George DL, Oren M. Wild type p53 can mediate sequence-specific transactivadon of an internal promoter within the mdm2 gene. Oncogene 1993;8:3411-6. (Pubitemid 23342640)
35. Leach FS, Tokino T, Meltzer P, et al. p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993;53:2231-4. (Pubitemid 23156805)
36. Ladanyi M, Cha C, Lewis RJhanwar SC, Huvos AG, HealeyJH. MDM2gene amplification in metastatic osteosarcoma. Cancer Res 1993;53:16-8.
37. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224:1121-4. (Pubitemid 14106392)
38. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N EnglJ Med 1985;313:1111-6. (Pubitemid 16216827)
39. Brodeur GM, Fong CT. Molecular biology and genetics of human neuroblastoma. Cancer Genet Cytogenet 1989;41:153-74. (Pubitemid 19257069)
40. Brodeur GM, Azar C, Brother M, et al. Neuroblastoma: Effect of genetic factors on prognosis and treatment. Cancer 1992;70:1685-94.
41. Tsuda H, Shimosato Y, Upton MP, YokotaJ, Terada M, Ohira M. Retrospective study on amplification of N-myc and c-myc genes in pediatric solid tumors and its association widi prognosis and tumor differentiation. Lab Invest 1988;59:321-7.
42. Garson JA, Clayton J, Mclntyre P, KemsheadJT. N-jwyconcogene amplification in rhabdomyosarcoma at release. Lancet 1986;1:1496.
43. Mitani K, Kurosawa H, Suzuki A, etal. Amplification of N-myc'm a rhabdomyosarcoma. Jpn J Cancer Res 1986;77:1062-5.
44. Maillet MW, Robinson RA, Burgart LJ. Genomic alterations in sarcomas: A histologic correlative study widi use of oncogene panels. Mod Pathol 1992;5:410-4.
45. Krajewski S, Chatten J, Hanada M, Reed JC. Immunohistochemical analysis of the bcl-2 oncoprotein in human neuroblastomas: Comparisons with tumor cell differentiation and N-myc protein. Lab Invest 1995;72:42-54.
46. Kerr JFR, Winterford CM, Harmon BV. Morphological criteria for identifying apoptosis. Cell Biol 1994;1:319-29.
47. Tilly JL. Use of the terminal transferase DNA labeling reaction for the biochemical and in situ analysis of apoptosis. Cell Biol 1994;1:330-7.